Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Atara Biotherapeutics, Inc. - Common Stock
(NQ:
ATRA
)
4.900
+0.130 (+2.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atara Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket
↗
July 13, 2022
Gainers
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
↗
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
↗
May 23, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
July 12, 2022
Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion.
Via
Benzinga
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
July 12, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 08, 2022
Via
Benzinga
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
July 06, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
↗
June 30, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
Via
Benzinga
Dow Jumps 150 Points; Icosavax Shares Plunge
↗
June 29, 2022
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.
Via
Benzinga
89 Biggest Movers From Friday
↗
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
June 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Where Atara Biotherapeutics Stands With Analysts
↗
May 24, 2022
Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know
↗
May 23, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1%...
Via
Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
↗
May 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 20, 2022
Via
Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
↗
May 20, 2022
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 19, 2022
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's market cap stands at $330.1 million.
Via
Benzinga
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
May 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
↗
May 10, 2022
Upgrades
Via
Benzinga
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
May 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Earnings Preview
↗
May 04, 2022
Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara...
Via
Benzinga
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
April 28, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 22, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
April 05, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
↗
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
